



Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

Citation

Siegel, D. S., P. Richardson, M. Dimopoulos, P. Moreau, C. Mitsiades, D. Weber, J. Houp, et al. 2014. "Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma." *Blood Cancer Journal* 4 (4): e202. doi:10.1038/bcj.2014.23. <http://dx.doi.org/10.1038/bcj.2014.23>.

Published Version

doi:10.1038/bcj.2014.23

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:12153006>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available. Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

CORRIGENDUM

Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma

DS Siegel^{1,9,10}, P Richardson^{2,9}, M Dimopoulos³, P Moreau⁴, C Mitsiades¹, D Weber⁵, J Houp⁶, C Gause⁶, S Vuocolo⁶, J Eid⁶, T Graef⁷ and KC Anderson⁸

Blood Cancer Journal (2014) 4, e202; doi:10.1038/bcj.2014.23; published online 11 April 2014

Correction to: *Blood Cancer Journal* (2014) 4, e182; doi:10.1038/bcj.2014.1; published online 21 February 2014

Since the publication of this article, the authors have identified an error concerning one of the author affiliation addresses. KC Anderson was incorrectly affiliated to the following address: 'Merck & Co. Inc., Whitehouse Station, NJ, USA'. The correct address details are shown here.

The article has also been rectified, and now carries the correct information.

The Authors would like to apologise for any inconvenience this may have caused.

¹Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; ²Dana-Farber Cancer Institute, Boston, MA, USA; ³Department of Clinical Therapeutics, University of Athens, Athens, Greece; ⁴University Hospital, Nantes, France; ⁵MD Anderson Cancer Center, Houston, TX, USA; ⁶Merck & Co. Inc., Whitehouse Station, NJ, USA; ⁷Pharmacyclics Inc., Sunnyvale, CA, USA and ⁸Department of Medicine, Harvard Medical School and Kraft Family Blood Center, Dana-Farber Cancer Institute, Boston, MA, USA. Correspondence: Dr DS Siegel, Myeloma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ 07601, USA. E-mail: DSiegel@HackensackUMC.org

⁹These authors contributed equally to this work.

¹⁰As corresponding author, Dr Siegel assumes full responsibility for the overall content and integrity of the manuscript.